# US 2016/0257689 A1 · Salts and processes of preparing a pi3k inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257689 A1
- Document ID: US20160257689A1
- Status: Published application
- Kind: A1
- Application number: 15/054,474
- Filed: 2016-02-26
- Published: 2016-09-08
- Earliest claimed: 2015-02-27
- Assignees: Incyte Corporation
- Applicants: Incyte Corporation
- Inventors: Lei Qiao; Lingkai Weng; ChongShen Eric Shi; David Meloni; Qiyan Lin; Michael Xia; Vaqar Sharief; William Frietze; Zhongjiang Jia; Yongchun Pan; Pingli Liu; Tai-Yuen Yue; Jiacheng Zhou
- Web page: https://patentgrep.com/patent/US20160257689A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/08: of the prostate
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present application provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor phosphoinositide 3-kinase-delta (PI3Kδ), as well as a salt form and intermediates related thereto.

## Claims

### Claim 1

A salt which is (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one hydrochloric acid salt.

### Claim 2 (depends on 1)

The salt of claim 1 that is a 1:1 stoichiometric ratio of (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one to hydrochloric acid.

### Claim 3 (depends on 1)

The salt of claim 1 that is crystalline.

### Claim 4 (depends on 1)

The salt of claim 1 that is substantially isolated.

### Claim 5 (depends on 1)

The salt of claim 1 characterized by a DSC thermogram having an endothermic peak at about 207° C.

### Claim 6 (depends on 1)

The salt of claim 1 having a DSC thermogram substantially as shown in FIG. 1.

### Claim 7 (depends on 1)

The salt of claim 1 having a TGA thermogram substantially as shown in FIG. 2.

### Claim at position 8

8-10. (canceled)

### Claim 11 (depends on 1)

The salt of claim 1 having at least four XRPD peaks, in terms of 2-theta, selected from about 11.3°, about 16.4°, about 21.0°, about 23.0°, about 28.1°, about 31.2°, and about 32.8°.

### Claim 12 (depends on 1)

The salt of claim 1 having at least five XRPD peaks, in terms of 2-theta, selected from about 11.3°, about 16.4°, about 21.0°, about 23.0°, about 28.1°, about 31.2°, and about 32.8°.

### Claim 13 (depends on 1)

The salt of claim 1 having an XRPD profile substantially as shown in FIG. 3.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising a salt of claim 1 and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 1)

A method of inhibiting an activity of a PI3K kinase, comprising contacting the kinase with a salt of claim 1.

### Claim 16 (depends on 15)

The method of claim 15, wherein the PI3K is PI3Kδ.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A method of treating a disease in a patient, wherein said disease is associated with abnormal expression or activity of a PI3K kinase, comprising administering to said patient a therapeutically effective amount of a salt of claim 1.

### Claim at position 17

19-30. (canceled)

### Claim 31 (depends on 1)

A process of preparing the salt of claim 1, comprising reacting a compound of Formula I:
with hydrochloric acid to form said salt.

### Claim 32 (depends on 31)

The process of claim 31, wherein said hydrochloric acid is 1 M aqueous hydrochloric acid.

### Claim 33 (depends on 31)

The process of claim 31, wherein about 3.3 to about 3.7 equivalents of hydrochloric acid is used based on 1 equivalent of the compound of Formula I.

### Claim 34 (depends on 31)

The process of claim 31, wherein said reacting is performed at a temperature of from about 45° C. to about 55° C.

### Claim 35 (depends on 31)

The process of claim 31, wherein the process comprises:
adding hydrochloric acid to the compound of Formula I at room temperature to form a slurry;
heating said slurry to a temperature of from about 45° C. to about 55° C. to form a solution; and
cooling the solution to a temperature of from about 0° C. to about 5° C. to crystallize said salt.

### Claim 36

A process, comprising reacting a compound of Formula XVI:
with formamidine acetate to form a compound of Formula I:

### Claim at position 24

37-39. (canceled)

### Claim 40 (depends on 36)

The process of claim 36, further comprising preparing the compound of Formula XVI by a process comprising reacting a compound of Formula XV:
with (1-ethoxyethylidene)malononitrile in the presence of a tertiary amine.

### Claim 41 (depends on 40)

The process of claim 40, wherein said tertiary amine is N-methylpyrrolidinone.

### Claim 42

(canceled)

### Claim 43 (depends on 40)

The process of claim 40, further comprising preparing the compound of Formula XV by a process comprising reacting a compound of Formula XIV-a:
with hydrazine in the presence of a tertiary amine, wherein P1 is C1-6alkylsulfonyl.

### Claim 44 (depends on 43)

The process of claim 43, wherein said tertiary amine is N-methylpyrrolidinone.

### Claim 45 (depends on 43)

The process of claim 43, wherein said reacting of the compound of Formula XIV-a with hydrazine is performed at a temperature of from about 35° C. to about 60° C.

### Claim 46

(canceled)

### Claim 47 (depends on 43)

The process of claim 43, wherein P1 is methanesulfonyl group.

### Claim 48 (depends on 43)

The process of claim 43, further comprising preparing the compound of Formula XIV by a process comprising reacting a compound of Formula XIII:
with C1-6 alkylsulfonylhalide in the presence of a tertiary amine.

### Claim 49 (depends on 48)

The process of claim 48, wherein said C1-6 alkylsulfonylhalide is methanesulfonyl chloride.

### Claim 50 (depends on 48)

The process of claim 48, wherein said tertiary amine is N,N-diisopropylethylamine.

### Claim at position 36

51-53. (canceled)

### Claim 54 (depends on 48)

The process of claim 48, wherein the steps of: (i) reacting of said compound of Formula XIII with C1-6 alkylsulfonylhalide; (ii) reacting said compound of Formula XIV-a with hydrazine in the presence of a tertiary amine to form a compound of Formula XV; and (iii) reacting said compound of Formula XV with formamidine acetate to form a compound of Formula XVI are conducted in the same pot without isolation of the compound of Formula XIV-a or the compound of Formula XV.

### Claim 55 (depends on 36)

The process of claim 36, further comprising preparing the compound of Formula XVI by a process comprising reacting a salt of Formula XV-a:
with (1-ethoxyethylidene)malononitrile in the presence of a tertiary amine, wherein TsOH is p-toluenesulfonic acid.

### Claim at position 39

56-59. (canceled)

### Claim 60 (depends on 55)

The process of claim 55, further comprising preparing the salt of Formula XV-a by a process comprising reacting a compound of Formula XXI:
with p-toluenesulfonic acid, wherein Boc is tert-butoxycarbonyl.

### Claim 61 (depends on 60)

The process of claim 60, wherein said p-toluenesulfonic acid is p-toluenesulfonic acid monohydrate.

### Claim at position 42

62-64. (canceled)

### Claim 65 (depends on 60)

The process of claim 60, wherein the steps of: (i) reacting said compound of Formula XXI with p-toluenesulfonic acid to form a salt of Formula XV-a; and (ii) reacting said salt of Formula XV-a with (1-ethoxyethylidene)malononitrile are conducted in the same pot without isolation of the salt of Formula XV-a.

### Claim 66 (depends on 60)

The process of claim 60, further comprising preparing the compound of Formula XXI by a process comprising reacting a compound of Formula XX:
with hydrogen gas in the presence of one or more independently selected hydrogenation catalysts, wherein Boc is t-butoxycarbonyl.

### Claim 67 (depends on 66)

The process of claim 66, wherein said reacting of the compound of Formula XX with hydrogen gas is performed in the presence of two independently selected hydrogenation catalysts.

### Claim 68 (depends on 67)

The process of claim 67, wherein one hydrogenation catalyst is bis(1,5-cyclooctadiene)rhodium(I)tetrafluoroborate and the other is (R)-(−)-1-{(S)-2-[bis(4-trifluoromethylphenyl)phosphine]ferrocenyl}ethyl-di-t-butylphosphine.

### Claim at position 47

69-72. (canceled)

### Claim 73 (depends on 66)

The process of claim 66, further comprising preparing the compound of Formula XX by a process comprising reacting a compound of Formula XIX:
with t-butyl carbazate.

### Claim at position 49

74-75. (canceled)

### Claim 76 (depends on 73)

The process of claim 73, further comprising preparing the compound of Formula XIX by a process comprising oxidizing a compound of Formula XIII-a:
in the presence of an oxidizing agent.

### Claim 77 (depends on 76)

The process of claim 76, wherein said oxidizing agent is Dess-Martin periodinane.

### Claim at position 52

78-80. (canceled)

### Claim 81

A compound selected from compounds of Formula XIV, XV, XVI, XIX, XX, and XXI:
or a pharmaceutically acceptable salt thereof.

### Claim at position 54

82-86. (canceled)
